Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.65 |
| ▸ | XDH | P47989 | 1/20 | 0.61 |
| ▸ | ALDH2 | P05091 | 13/20 | 0.58 |
| ▸ | MAOA | P21397 | 8/20 | 0.58 |
| ▸ | MAOB | P27338 | 8/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | BCL2 | P10415 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17938824 | 0.94 | XDH (0.71) | STSXDHALDH2MAOAMAOB | |
| SCHEMBL571388 | 0.91 | MAOA (0.71) | XDHALDH2MAOAMAOBMAPT | |
| SCHEMBL18872545 | 0.84 | STS (0.66) | STSXDHALDH2MAOAMAOB | |
| SCHEMBL17991978 | 0.82 | MAPT (0.50) | STSXDHALDH2MAOAMAOB | |
| SCHEMBL17988679 | 0.82 | STS (0.48) | STSXDHALDH2MAOAMAOB | |
| SCHEMBL16401100 | 0.82 | XDH (0.73) | XDHALDH2MAOAMAOBMAPT | |
| SCHEMBL17938829 | 0.81 | NPC1 (0.67) | XDHALDH2MAOAMAOBMAPT | |
| SCHEMBL12238001 | 0.81 | STS (0.61) | STSXDHALDH2MAOAMAOB | |
| SCHEMBL12325763 | 0.81 | STS (0.76) | STSXDHALDH2MAOAMAOB | |
| SCHEMBL17991990 | 0.80 | MAPT (0.58) | STSXDHMAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3862002-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3354282-B1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| EP-3071235-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016122889-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| EP-2898923-A2 | Isoflavones for regulating sirtuin gene expression | Nestec S.A. (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-08-21 | — | — | US | disclosed |
| US-8748177-B2 | Compositions for proliferation of cells and related methods | THE HOSPITAL FOR SICK CHILDREN (CA) | 2014-06-10 | — | — | US | disclosed |
| US-20140039047-A1 | METHODS FOR REGULATING SIRTUIN GENE EXPRESSION | PAN YUANLONG (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140037583-A1 | METHODS AND COMPOSITIONS SUITABLE FOR PREVENTING AND TREATING HYPERLEPTINEMIA | PAN YUANLONG (US) | 2014-02-06 | — | — | US | disclosed |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2011-12-08 | — | — | US | disclosed |
| WO-2010039679-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | THE HOSPITAL FOR SICK CHILDREN (CA) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234271-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | STS 1309/4885XDH 4441/4885ALDH2 1826/4885 |
| US-20110301105-A1 | COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS | MKI67, KRT18, PROX1 | STS 1309/4885XDH 4441/4885ALDH2 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.